author-photo

Azadeh Cheraghchi-Bashi-Astaneh

Imperial College London

4

Papers

1

Citations

Citation Trend

Filter By

Papers (4) Sort By

JournalConferenceOthers

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

2020 Epidemiology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PR04: DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling

2013 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号